{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-024088","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.213471+00:00","generated_at":"2026-05-17T12:43:49.247692+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elite Q1 revenue $40.2M, up 114% YoY; operating profit $21.7M, up 462%","bullets":["Consolidated revenues of $40.2M for Q1 FY2026, a 114% increase YoY from the prior year comparable period.","Operating profits of $21.7M, a 462% increase YoY, driven by sales of lisdexamfetamine products and strong Elite label growth.","Lisdexamfetamine products launched after the prior year Q1, contributing significantly to the top-line expansion.","Company will host a conference call on August 15, 2025 at 11:30 AM EDT to discuss results and provide a business update."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-024088","json":"https://secwatch.observer/filing/0001641172-25-024088.json","markdown":"https://secwatch.observer/filing/0001641172-25-024088.md","text":"https://secwatch.observer/filing/0001641172-25-024088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000164117225024088/0001641172-25-024088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000164117225024088/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:43:49.247692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}